<DOC>
	<DOCNO>NCT00523731</DOCNO>
	<brief_summary>Study title : A Study Blood-Borne Autologous Angiogenic Cell Precursors Therapy Patients Critical Limb Ischemia ( ACPs-CLI ) Principle Investigator : Assoc.Prof . Pramook Mutirangura , M.D . Head Division Vascular Surgery , Department Surgery , Faculty Medicine Siriraj Hospital , Mahidol University , BKK , Thailand Study objective : To determine safety efficacy intramuscular injection blood-borne autologous ACPs relieving symptom critical limb ischemia patient treat maximal medical therapy n't intravascular operative revascularization option . Study Design : A pilot study , single center , non-randomized , open-label trial . Total expected . patient : 6 main selection criterion : A . Subjects one clinical indication diagnostic CLI : distal extremity pain rest require subject use analgesic &gt; 2 week ; peripheral ischemic ulcer ( ) ; area gangrene ; non-healing ischemic ulcer AND B . Subjects one follow hemodynamic indicator severe peripheral arterial occlusive disease : I. Ankle brachial index &lt; 0.45 II . Toe brachial index &lt; 0.35 III . TcPO2 / TcO2 &lt; 40 mmHg . C. The subject poor candidate standard revascularization treatment peripheral arterial disease , base inadequate bypass conduit , unfavorable anatomy D. Age 18 80 year Investigational Product : At D-8 250 ml blood drawn patient production autologous EPCs ACPs ( VescellTM ) . On D0 , least 1.5 million ACPs viability &gt; 75 % suspend 30 ml sterile cell culture medium inject 1.5 cm deep 1.5 apart 23 -gauge needle gastrocnemius muscle leg chosen ( ischemic leg ) treatment . For injection planning grid 10X10 cm prepare point 1 ml ACPs suspension inject . The study consist 4 period : Screening ( D-14 to-9 &amp; D-8 , Treatment ( D0 ) , Acute Safety follow-up ( D1 &amp; D2 ) , Chronic follow-up ( D30 &amp; D90 ) period , total follow-up case 3 month . Evaluation criterion : Safety : no. &amp; duration adverse event &amp; serious adverse event Efficacy : Attenuate CLI patient symptom ( Rest pain , Pain-free walk distance , Ulcer size &amp; Gangrene dimension intensity )</brief_summary>
	<brief_title>ACPs Severe PAD/CLI Direct Intramuscular Injection</brief_title>
	<detailed_description>Six patient Critical Limb Ischemia ( CLI ) severe Peripheral Arterial Disease ( PAD ) enrol , screen , treat injection Blood-Borne Autologous Angiogenic Cell Precursors ( ACPs ) gastrocnemius ischemic leg intramuscular regional anesthesia . Following injection .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Subjects one clinical indication diagnostic CLI : distal extremity pain rest require subject use analgesic &gt; 2 week ; peripheral ischemic ulcer ( ) ; area gangrene ; nonhealing ischemic ulcer AND Subjects one follow hemodynamic indicator severe peripheral arterial occlusive disease : Ankle brachial index &lt; 0.45 Toe brachial index &lt; 0.35 TcPO2 / TcO2 &lt; 40 mmHg . The subject poor candidate standard revascularization treatment option peripheral arterial disease , base inadequate bypass conduit , unfavorable anatomy Age 18 80 year Male nonpregnant , nonlactating female Informed consent obtain consent form sign Patient angiography meaningful supra popliteal occlusion may relate symptom CLI . Subjects , opinion investigator , vascular disease prognosis indicate would require major amputation ( ankle ) within 4 week start treatment Patient receive blood transfusion previous 4 week ( exclude potential nonautologous ACPs harvest blood ) . Inability communicate ( may interfere clinical evaluation patient ) Major operation precede 3 month Myocardial infarction brain infarction uncontrolled myocardial ischemia persistent severe heart failure ( EF &lt; 25 % ) precede 3 month Significant valvular disease valve replacement precede 3 month After heart transplantation Severe cardiomyopathy ( EF &lt; 25 % ) Renal failure ( creatinine &gt; 2 mg/dl ) Hepatic failure Anemia ( low 11mg/dl.hemoglobin female low 12 mg/dl male ) Abnormal coagulation test [ platelet , PT ( INR ) , PTT ] Stroke within precede 3 year Malignancy within precede 3 year Concurrent chronic acute infectious disease Severe concurrent medical disease ( e.g. , septicemia , HIV1,2/HBV/HCV infection , poorly control insulindependent diabetes mellitus ; HBA1c &gt; 8 % proliferative retinopathy , systemic lupus erythematosus , multiple sclerosis , amyotrophic lateral sclerosis ) Chronic immunomodulating cytotoxic drug treatment Patients rectal temp . 38.40C 2 consecutive day Patient unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>Rest pain</keyword>
	<keyword>claudication</keyword>
	<keyword>chronic ischemic non-healing ulcer</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>no-option case</keyword>
</DOC>